CHMP follows FDA lead on Avastin in cervical cancer
This article was originally published in Scrip
Executive Summary
The EU's CHMP has recommended expanding the EU label for Roche's targeted anticancer Avastin (bevacizumab) for use in the new indication of cervical cancer.